The latest announcement is out from AN2 Therapeutics, Inc. (ANTX).
AN2 Therapeutics, Inc. is undergoing a significant restructure, slashing its workforce by 50% to conserve capital and realign its focus after halting the EBO-301 study. This downsizing will cost an estimated $2-$3 million in severance and related charges by the end of 2024. Furthermore, Dr. Paul Eckburg, the Chief Medical Officer, is set to leave but will remain as a consultant for a year. Despite the EBO-301 study’s termination due to insufficient results in a key secondary endpoint, it did achieve its primary objective, offering some positive insights into the novel patient-reported outcome tool used in the research.
For detailed information about ANTX stock, go to TipRanks’ Stock Analysis page.